1. Home
  2. PHIO vs TSBX Comparison

PHIO vs TSBX Comparison

Compare PHIO & TSBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHIO
  • TSBX
  • Stock Information
  • Founded
  • PHIO 2011
  • TSBX 2015
  • Country
  • PHIO United States
  • TSBX United States
  • Employees
  • PHIO N/A
  • TSBX N/A
  • Industry
  • PHIO Biotechnology: Pharmaceutical Preparations
  • TSBX
  • Sector
  • PHIO Health Care
  • TSBX
  • Exchange
  • PHIO Nasdaq
  • TSBX Nasdaq
  • Market Cap
  • PHIO 8.6M
  • TSBX 7.7M
  • IPO Year
  • PHIO N/A
  • TSBX 2023
  • Fundamental
  • Price
  • PHIO $2.00
  • TSBX $0.33
  • Analyst Decision
  • PHIO Strong Buy
  • TSBX Buy
  • Analyst Count
  • PHIO 1
  • TSBX 3
  • Target Price
  • PHIO $4.00
  • TSBX $4.75
  • AVG Volume (30 Days)
  • PHIO 875.3K
  • TSBX 91.5K
  • Earning Date
  • PHIO 05-15-2025
  • TSBX 05-08-2025
  • Dividend Yield
  • PHIO N/A
  • TSBX N/A
  • EPS Growth
  • PHIO N/A
  • TSBX N/A
  • EPS
  • PHIO N/A
  • TSBX N/A
  • Revenue
  • PHIO N/A
  • TSBX N/A
  • Revenue This Year
  • PHIO N/A
  • TSBX N/A
  • Revenue Next Year
  • PHIO N/A
  • TSBX N/A
  • P/E Ratio
  • PHIO N/A
  • TSBX N/A
  • Revenue Growth
  • PHIO N/A
  • TSBX N/A
  • 52 Week Low
  • PHIO $0.97
  • TSBX $0.29
  • 52 Week High
  • PHIO $9.79
  • TSBX $3.05
  • Technical
  • Relative Strength Index (RSI)
  • PHIO 54.98
  • TSBX 43.91
  • Support Level
  • PHIO $1.71
  • TSBX $0.32
  • Resistance Level
  • PHIO $2.08
  • TSBX $0.35
  • Average True Range (ATR)
  • PHIO 0.13
  • TSBX 0.02
  • MACD
  • PHIO 0.01
  • TSBX -0.00
  • Stochastic Oscillator
  • PHIO 76.32
  • TSBX 25.43

About PHIO Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.

About TSBX Turnstone Biologics Corp.

Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.

Share on Social Networks: